
  
    
      
        
        Obesity_NNP ,_, in_IN particular_JJ visceral_NN adiposity_NN ,_, is_VBZ positively_RB correlated_JJ with_IN insulin_NN
        resistance_NN and_CC type_NN 2_CD diabetes_NN ._. Although_IN the_DT link_NN is_VBZ well_RB established_VBN in_IN humans_NNS and_CC in_IN
        rodent_NN models_NNS ,_, the_DT mechanisms_NNS involved_VBN in_IN obesity-related_JJ insulin_NN resistance_NN are_VBP not_RB clear_JJ ._.
        One_CD possibility_NN is_VBZ that_WDT hormones_NNS secreted_JJ by_IN adipocytes_NNS compromise_NN peripheral_JJ insulin_NN
        sensitivity_NN ,_, and_CC a_DT number_NN of_IN candidates_NNS for_IN such_JJ adipocyte_NN signals_NNS have_VBP been_VBN identified_VBN ._.
        One_CD of_IN them_PRP ,_, resistin_NN ,_, was_VBD discovered_VBN a_DT few_JJ years_NNS ago_RB by_IN Mitchell_NNP Lazar_NNP and_CC colleagues_NNS ,_, who_WP
        showed_VBD that_IN the_DT protein_NN is_VBZ expressed_VBN by_IN mouse_NN adipocytes_NNS and_CC regulated_VBN by_IN a_DT group_NN of_IN
        anti-diabetic_JJ drugs_NNS called_VBD thiazolidinediones_NNS ._. Several_JJ lines_NNS of_IN evidence_NN from_IN functional_JJ
        studies_NNS in_IN rodents_NNS suggested_VBD that_DT resistin_NN could_MD be_VB the_DT missing_VBG mechanistic_JJ link_NN between_IN
        obesity_NN and_CC diabetes_NN ._.
        The_DT human_JJ homolog_NN of_IN resistin_NN has_VBZ subsequently_RB been_VBN under_IN intense_JJ investigation_NN ,_, but_CC
        initial_JJ studies_NNS revealed_VBD more_JJR differences_NNS than_IN similarities_NNS between_IN the_DT human_NN and_CC rodent_NN
        proteins_NNS :_: human_JJ resistin_NN is_VBZ mostly_RB expressed_VBN in_IN macrophages_NNS ,_, not_RB in_IN adipocytes_NNS ,_, and_CC its_PRP$
        serum_NN levels_NNS do_VBP not_RB correlate_VBP as_RB clearly_RB with_IN obesity_NN ,_, insulin_NN resistance_NN ,_, or_CC diabetes_NN ._.
        Similarly_RB ,_, genetic_JJ association_NN studies_NNS between_IN allelic_JJ variants_NNS of_IN the_DT resistin_NN gene_NN and_CC
        metabolic_JJ abnormalities_NNS have_VBP so_RB far_RB been_VBN inconclusive_JJ ._. These_DT results_NNS prompted_VBD some_DT of_IN the_DT
        scientists_NNS in_IN the_DT field_NN who_WP had_VBD jumped_VBN on_IN the_DT resistin_NN bandwagon_NN after_IN the_DT initial_JJ results_NNS
        in_IN rodents_NNS to_TO jump_VB off_RP again_RB ._. Others_NNS ,_, including_VBG the_DT resistin_NN discoverers_NNS ,_, continue_VB their_PRP$
        quest_NN to_TO uncover_VB resistin_NN 's_POS role_NN in_IN humans_NNS ,_, and_CC have_VBP started_VBN to_TO think_VB outside_IN the_DT framework_NN
        defined_VBN by_IN the_DT mouse_NN data_NN ._.
        Starting_VBG with_IN the_DT role_NN of_IN macrophages_NNS in_IN inflammation_NN and_CC encouraged_VBN by_IN the_DT fact_NN that_DT
        obesity_NN and_CC insulin_NN resistance_NN are_VBP associated_VBN with_IN markers_NNS of_IN systemic_JJ inflammation_NN ,_, Lazar_NNP
        and_CC colleagues_NNS examined_VBD the_DT resistin_NN response_NN to_TO inflammatory_JJ stimulators_NNS ._. As_IN they_PRP report_VBP
        in_IN this_DT issue_NN ,_, resistin_NN production_NN in_IN macrophages_NNS and_CC serum_NN levels_NNS in_IN patients_NNS are_VBP
        significantly_RB increased_VBN by_IN these_DT stimulators_NNS ._. This_DT response_NN can_MD be_VB blocked_VBN by_IN the_DT
        thiazolidinedione_NN rosiglitazone_NN and_CC by_IN aspirin_NN ,_, two_CD drugs_NNS that_WDT have_VBP dual_JJ anti-inflammatory_JJ
        and_CC insulin-sensitizing_JJ actions_NNS and_CC antagonize_VB the_DT immune_JJ regulator_NN NF-kappaB_NNP ._. The_DT
        researchers_NNS go_VBP on_IN to_TO show_VB that_DT activation_NN of_IN NF-kappaB_NNP is_VBZ sufficient_JJ to_TO induce_VB resistin_NN
        expression_NN ._. And_CC NF-kappaB_NNP is_VBZ necessary_JJ for_IN the_DT resistin_NN response_NN to_TO inflammatory_JJ
        stimuli_NNS ._.
        Lazar_NNP and_CC colleagues_NNS now_RB view_VBP obesity_NN as_IN a_DT state_NN of_IN chronic_JJ inflammation_NN and_CC speculate_VB
        that_IN in_IN obese_NN individuals_NNS inflammatory_JJ cytokines_NNS lead_VBP to_TO elevated_VBD production_NN of_IN resistin_NN by_IN
        macrophages_NNS and_CC elevated_VBD serum_NN resistin_NN levels_NNS ,_, which_WDT in_IN turn_NN contribute_VB to_TO insulin_NN
        resistance_NN and_CC diabetes_NN ._. This_DT is_VBZ consistent_JJ with_IN some_DT studies_NNS that_WDT have_VBP found_VBN higher_JJR
        resistin_NN levels_NNS in_IN obese_NN individuals_NNS and_CC patients_NNS with_IN insulin_NN resistance_NN and_CC /_NN or_CC diabetes_NN ,_,
        but_CC not_RB all_DT studies_NNS have_VBP found_VBN such_JJ differences_NNS ._.
        Jeffrey_NNP Flier_NNP ,_, an_DT obesity_NN researcher_NN who_WP was_VBD not_RB involved_VBN in_IN the_DT study_NN ,_, calls_VBZ the_DT
        article_NN “ an_DT excellent_JJ and_CC timely_JJ paper_NN that_WDT demonstrates_VBZ the_DT fact_NN that_IN inflammatory_JJ
        pathways_NNS induce_VB resistin_NN expression_NN and_CC levels_NNS in_IN human_JJ monocytes_NNS ex_FW vivo_NN ,_, and_CC in_IN intact_JJ
        humans_NNS ._. The_DT work_NN appears_VBZ to_TO provide_VB a_DT novel_NN link_NN between_IN inflammation_NN and_CC insulin_NN
        resistance_NN ,_, through_IN monocyte_NN derived_VBD resistin_NN ._.” He_PRP points_VBZ out_IN ,_, however_RB ,_, that_IN “ several_JJ other_JJ
        factors_NNS also_RB appear_VBP to_TO contribute_VB directly_RB to_TO insulin_NN resistance_NN in_IN inflammation_NN (_( e_SYM ._. g_SYM ._. ,_,
        cytokines_NNS themselves_PRP ,_, without_IN invoking_VBG resistin_NN )_) so_IN the_DT full_JJ biologic_JJ implications_NNS of_IN the_DT
        high_JJ resistin_NN levels_NNS for_IN insulin_NN resistance_NN in_IN humans_NNS cannot_NN be_VB determined_VBN from_IN this_DT
        study_NN ._.” Resistin_NNP ,_, it_PRP seems_VBZ ,_, continues_VBZ to_TO resist_VB easy_JJ interpretations_NNS ._.
      
    
  
